Relationship between clinical toxicities and ERCC1 rs3212986 and XRCC3 rs861539 polymorphisms in cervical cancer patients
- 7 July 2017
- journal article
- research article
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 33 (1) , 116-123
Abstract
Background: Several studies have suggested that there are single nucleotide polymorphisms (SNPs) that can be considered potential biomarkers in the prognosis and therapeutic response of cancer patients. The present study investigated the association between ERCC1 rs3212986 and XRCC3 rs861539 polymorphisms and clinical toxicities induced by chemoradiotherapy (CRT) in cervical cancer. Methods: This hospital-based retrospective cohort study included 260 patients with cervical cancer, FIGO stages Ib2-IVa, who underwent CRT (cisplatin). Genetic polymorphisms analysis was performed by allelic discrimination with real-time polymerase chain reaction (RT-PCR). Results: Our results indicated a link between ERCC1 rs3212986 and the onset of late gastrointestinal toxicity (p = 0.038). Furthermore, using a recessive model (AA vs. CC/CA), we found that patients carrying AA homozygous genotype presented a fourfold increased risk of developing late gastrointestinal toxicity when compared with patients with the C allele (odds ratio = 3.727, 95% confidence interval, 1.199-11.588; p = 0.017). No association was found regarding the XRCC3 rs861539 polymorphism and any clinical toxicity event. Conclusions: This is the first study evaluating the relationship between these polymorphisms and clinical toxicities in cervical cancer patients submitted to CRT with cisplatin. These results may contribute toward a better understanding of the influence of genetic polymorphisms in genes associated with DNA repair in the clinical response to CRT of patients with cervical cancer.Keywords
This publication has 38 references indexed in Scilit:
- ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinomaRadiation Oncology, 2012
- ERCC1 C19007T polymorphism and the risk and invasiveness of cervical cancer in Korean womenAsia-Pacific Journal of Clinical Oncology, 2012
- Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation aloneRadiotherapy and Oncology, 2010
- Detecting Genotyping Error Using Measures of Degree of Hardy-Weinberg DisequilibriumStatistical Applications in Genetics and Molecular Biology, 2010
- Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancerBritish Journal of Cancer, 2009
- XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese populationLung Cancer, 2008
- G. H. Hardy (1908) and Hardy–Weinberg EquilibriumGenetics, 2008
- A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patientsCarcinogenesis, 2008
- The value of prognostic factors for uterine cervical cancer patients treated with irradiation aloneBMC Cancer, 2007
- Mitotic defects in XRCC3 variants T241M and D213N and their relation to cancer susceptibilityHuman Molecular Genetics, 2006